BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 2856924)

  • 1. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
    Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
    Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin.
    Finlay GJ; Ching LM; Wilson WR; Baguley BC
    J Natl Cancer Inst; 1987 Aug; 79(2):291-6. PubMed ID: 3474463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to 6-aminonicotinamide.
    Saunders PP; Muhs MA; Arimilli S
    Anticancer Res; 1996; 16(2):843-8. PubMed ID: 8687139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purine metabolism of human glioblastoma in vivo.
    Pillwein K; Chiba P; Knoflach A; Czermak B; Schuchter K; Gersdorf E; Ausserer B; Murr C; Goebl R; Stockhammer G
    Cancer Res; 1990 Mar; 50(5):1576-9. PubMed ID: 2154328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
    J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical mechanisms of resistance to tiazofurin.
    Jayaram HN
    Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and metabolism of 2-beta-D-ribofuranosylthiazole-4-carboxamide in human lymphoid tumor cells in culture.
    Earle MF; Glazer RI
    Cancer Res; 1983 Jan; 43(1):133-7. PubMed ID: 6182988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein.
    English D; Rizzo MT; Tricot G; Hoffman R
    J Immunol; 1989 Sep; 143(5):1685-91. PubMed ID: 2547872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique bioactivation of tiazofurin--studies with resistant cells.
    Kuttan R
    Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
    Sokoloski JA; Sartorelli AC
    Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase.
    Fridland A; Connelly MC; Robbins TJ
    Cancer Res; 1986 Feb; 46(2):532-7. PubMed ID: 3000575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation.
    Kharbanda SM; Sherman ML; Spriggs DR; Kufe DW
    Cancer Res; 1988 Nov; 48(21):5965-8. PubMed ID: 2901907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
    Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
    J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.